---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-008804"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-04-08T23:59:59+00:00"
generated_at: "2026-06-26T08:25:46.420914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology announces updated Phase 2 mCRPC data and preclinical ovarian cancer data for onvansertib

## Summary
- Arm C (12 mg/m2 onvansertib days 1-14) achieved 75% radiographic stable disease at 12 weeks vs 53% in Arm A.
- Median progression-free survival increased from 4.1 months in Arm A to 13.2 months to-date in Arm C.
- Combination of onvansertib with olaparib overcame PARP inhibitor resistance in BRCA1-mutant and wildtype PDX ovarian cancer models.
- Mutations in PTEN and MTOR were positively associated with treatment response in mCRPC trial patients.
- Disease control by PSA stabilization improved from 29% in Arm A to 45% in Arm C.

## SEC filing metadata
- accession: 0001628280-22-008804
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022008804/0001628280-22-008804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022008804/crdf-20220408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-008804
- JSON: https://secwatch.observer/filing/0001628280-22-008804.json
- Plain text: https://secwatch.observer/filing/0001628280-22-008804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.